What is Deep Genomics?
Deep Genomics operates at the intersection of artificial intelligence, RNA biology, and automation to pioneer novel drug development strategies for genetic disorders. The company's proprietary AI platform is designed to accelerate the discovery of RNA therapies by deciphering intricate biological data and pinpointing new therapeutic targets. By focusing on the root causes of genetic diseases, Deep Genomics aims to create highly targeted treatments, thereby expanding the therapeutic landscape for a wide spectrum of inherited conditions.
How much funding has Deep Genomics raised?
Deep Genomics has raised a total of $196.7M across 3 funding rounds:
Angel/Seed
$3.8M
Series A
$13M
Series C
$180M
Angel/Seed (2015): $3.8M with participation from True Ventures and Bloomberg
Series A (2017): $13M led by Khosla Ventures and True Ventures
Series C (2021): $180M supported by SoftBank Vision Fund 2, Fidelity Management & Research Company LLC, and CPP Investments
Key Investors in Deep Genomics
SoftBank Vision Fund 2
SoftBank Vision Fund 2 is a prominent investment fund known for its significant backing of technology and innovation companies globally.
CPP Investments
CPP Investments, the Canada Pension Plan Investment Board, is a professional investment management organization that invests in a diversified portfolio of assets to support the retirement of Canadians.
True Ventures
True Ventures is a venture capital firm that supports early-stage technology companies, particularly those focused on artificial intelligence and disruptive innovation.
What's next for Deep Genomics?
With its recent major strategic investment, Deep Genomics is poised to accelerate its research and development initiatives, potentially moving into later-stage clinical trials and expanding its therapeutic pipeline. The substantial capital infusion suggests a focus on scaling operations, further enhancing its AI platform, and forging strategic partnerships to bring its innovative RNA therapies to market. The company's trajectory indicates a move towards commercialization, aiming to address unmet needs in genetic medicine on a global scale.
See full Deep Genomics company page
